{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033504","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.973167+00:00","generated_at":"2026-05-25T11:03:51.876423+00:00","sec_items":["2.05","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025","bullets":["Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.","Estimated $2.2 million in severance and benefits costs, recognized in Q1 2025.","President and CSO Jaume Pons will depart in April 2025; eligible for annual salary and 12 months COBRA.","No replacement named; position eliminated; transition consulting agreement expected.","Reduction part of pipeline prioritization and cash preservation strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033504","json":"https://secwatch.observer/filing/0000950170-25-033504.json","markdown":"https://secwatch.observer/filing/0000950170-25-033504.md","text":"https://secwatch.observer/filing/0000950170-25-033504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/0000950170-25-033504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/alxo-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T11:03:51.876423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b91e63c54","claim":"Jaume Pons departed as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/0000950170-25-033504-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President and Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}